timothy sykes logo
ABVX Stock Gains Traction As Obefazimod Story Strengthens Thumbnail
G Google News

ABVX Stock Gains Traction As Obefazimod Story Strengthens

ELLIS HOBBS•UPDATED SEP. 28, 2026, 3:02 PM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

Abivax SA stocks have been trading up by 6.27 percent after promising clinical progress boosted investor confidence.

Key Takeaways

  • Strong Phase 3 data and a positive pre‑NDA FDA interaction for obefazimod, plus a ~€767M July equity raise, extend Abivax’s cash runway into Q4 2029 despite heavier R&D spending.
  • Goldman Sachs launched coverage of ABVX with a Buy rating and $155 target, calling obefazimod a uniquely positioned oral ulcerative colitis therapy with biologic‑like efficacy.
  • Truist trimmed its ABVX target from $155 to $151 but kept a Buy, citing steady NDA progress, commercial build‑out, and added combination and pipeline options.
  • Wedbush cut its ABVX target to $118 and kept a Neutral, arguing that the expected 2026 NDA filing and possible 2027 approval are already reflected in the share price.
  • Leadership changes at Abivax, including planned promotions for Chris Rabbat to CMO and Tim Kelly to CTO, point to a company gearing up for commercialization.

Candlestick Chart

Live Update At 15:02:29 EDT: On Monday, September 28, 2026 Abivax SA stock [NASDAQ: ABVX] is trending up by 6.27%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

ABVX trades like a classic late‑stage biotech: volatile on headlines, but with a clear fundamental story under the hood. In the last couple of weeks, Abivax SA has pulled back from the mid‑$110s to close near $96.77 on 2026/09/28. That is a meaningful retrace from recent highs, even as the core obefazimod thesis has strengthened.

Daily candles show ABVX failing to hold above $115–$120 and then grinding lower, suggesting profit‑taking after a strong run. Intraday, the 5‑minute chart on the latest session is tight, mostly between $95 and $97, showing consolidation rather than panic. For short‑term traders, that kind of range often signals a pause before the next directional move.

More Breaking News

On fundamentals, ABVX is all about future potential. Revenue is tiny at about $4.57M, yet the enterprise value sits around $7.24B. A price‑to‑sales ratio above 1,400 and price‑to‑book near 14.8 tell traders this is a high‑expectation name, not a value play. The balance sheet, though, is strong: cash and equivalents around $516.7M and working capital near $488.2M back up the long runway story. For traders, ABVX is a bet on successful execution, not current earnings.

Why Traders Are Watching ABVX Momentum

ABVX is getting attention for one main reason: obefazimod. Abivax SA just delivered strong Phase 3 data in ulcerative colitis and reported a positive pre‑NDA interaction with the FDA. That combination de‑risks the late‑stage profile. For a biotech, that is the moment traders wait for — when a story shifts from “science project” toward “real product.”

To fuel that shift, Abivax raised roughly €767M net in a July equity offering. That cash extends the runway into Q4 2029, even as losses widen from heavier R&D and commercial build‑out. Traders need to understand what that means: the company is deliberately spending now to prepare for a potential launch, not bleeding cash without a plan. The repurchase of royalty certificates also points to ABVX wanting more of the future economics if obefazimod hits.

Wall Street is largely lining up behind that vision. Goldman Sachs started coverage of ABVX with a Buy and a $155 target, highlighting obefazimod’s biologic‑like efficacy and novel mechanism as reasons it may stand out among ulcerative colitis therapies. That view matches a bullish broader Street stance, with average targets around $162–$164 in other coverage.

Truist stayed in the bull camp too, only nudging its target from $155 to $151 while praising the NDA progress and commercial infrastructure work. The pushback comes from Wedbush, which cut its ABVX target to $118 and kept a Neutral, arguing that the expected Q4 2026 NDA filing and possible Q4 2027 approval are already priced in. That split creates exactly the kind of tension momentum traders love — enough optimism to fuel rallies, but enough skepticism to feed short setups and sharp squeezes when news lands.

Conclusion

ABVX is no longer trading like a quiet, early‑stage biotech. With strong Phase 3 obefazimod data, a positive pre‑NDA read from the FDA, and cash visibility into 2029, Abivax SA is positioning itself as a potential commercial story in ulcerative colitis. The leadership reshuffle — promoting Chris Rabbat to CMO in Q4 2026 and bringing in former Caribou Biosciences CTO Tim Kelly — reinforces that pivot from pure R&D to launch preparation.

At the same time, ABVX’s chart is reminding traders that expectations are already high. The pullback from $115–$120 down toward the high‑$90s, combined with Wedbush’s $118 Neutral target, underscores how sensitive the stock is to valuation debates. A pricey multiple tied to minimal current revenue means every regulatory milestone, every launch detail, and every analyst note can move the tape fast.

For active traders, that is the real edge with ABVX: understanding that the story is fundamentally strong but far from risk‑free. The setup favors those who respect the volatility, map key levels, and react quickly when news confirms or challenges the obefazimod path. As Tim Sykes likes to say, “The market rewards prepared traders, not hopeful ones.” As millionaire penny stock trader and teacher Tim Sykes, says, “Consistency is key in trading; don’t let emotions dictate your trades.”. Use ABVX as a case study in doing the homework, planning your trades, and cutting losses fast when the story or the price action breaks. This analysis is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”